Loading candles…
Syncom Formulations, established in 1995, is a global pharmaceutical company engaged in the manufacture and marketing of a wide range of healthcare products. Its portfolio includes generic formulations, ethical drugs, and over-the-counter (OTC) products, serving both domestic and international markets. Operating primarily as a generic pharmaceutical player, the company has more than 400 registered products. Syncom Formulations exports its products to over 15 countries across Africa, Asia, and Latin America, contributing to its presence in these regions. The company operates within the pharmaceutical industry but does not have publicly listed shares or noted subsidiaries, founders, or key management information available.
This page is a live market overview for SYNCOM FORMU (I) LTD (SYNCOMF) on the NSE. As a listed security, SYNCOM FORMU (I) LTD is tracked in the Healthcare segment of the Indian cash market and is widely followed for price discovery, liquidity and sector exposure. Use this overview to review price action, session ranges and derivatives context for SYNCOMF before placing trades on tick2trade.
As of the latest feed, SYNCOMF last traded at ₹13.45 on NSE, up ₹0.27 (2.05%) from the previous close of ₹13.18. Today's session range is ₹13.11 – ₹13.49, against a 52-week band of ₹10.21 – ₹18.8. Traded volume today stands at 18.84L shares.
The overview consolidates an interactive price chart with multiple time ranges, recent market headlines, upcoming corporate events for SYNCOMF in one place so you do not need multiple screens during the session. Day and 52-week ranges help you judge whether SYNCOMF is trading near support, resistance or the middle of its recent band. Volume and depth, when available, add context on how aggressively the name is being bought or sold.
Equity overview pages are built for investors who want a single reference for SYNCOM FORMU (I) LTD before reading news, checking results or sizing a position. Corporate events and headlines in the side column surface catalysts that may explain sudden moves in SYNCOMF. Related stocks in the same sector appear at the bottom of the page for quick peer comparison.
For a full option chain with greeks, open-interest bias, max pain and multi-leg strategy tools, open the tick2trade terminal or visit the dedicated SYNCOMF option chain page linked from this overview.
| Results - FY26 |
| To consider and approve the financial results for the period ended March 31, 2026 and other business matters |
| 22 May 2026 |
| Results - FY25 | To consider and approve the financial results for the period ended December 31, 2025 and other business matters | 12 Feb 2026 |
| Results - FY25 | To consider and approve the financial results for the period ended September 30, 2025 and other business matters | 12 Nov 2025 |
| Results - FY25 | To consider and approve the financial results for the period ended Jun 30, 2025 and other business matters | 8 Aug 2025 |
| Results - FY25 | To consider and approve the financial results for the period ended March 31, 2025 and other business matters | 19 May 2025 |
Tick2trade is a brand/platform owned and operated by Besseggen InfoTech LLP, a SEBI Registered Stock Broker holding Registration No: INZ000213450, Member of NSE (Member Code: 90155) and BSE (Member Code: 6722). Investment in securities market are subject to market risks; read all related documents carefully before investing.